

A preference trial with naratriptan 2.5 mg and paracetamol 1000 mg in migraine patients in the general practice

Submission date 16/05/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 16/05/2005	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 02/04/2008	Condition category Nervous System Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr N.J. Wiendels

Contact details

Leiden University Medical Center (LUMC)

Department of Neurology, K5Q-106

P.O. Box 9600

Leiden

Netherlands

2300 RC

+31 (0)71 526 1730

N.J.Wiendels@lumc.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

Study objectives

Traditional efficacy outcome measures in migraine trials are not sensitive enough to detect clinically relevant differences between two active agents. A promising novel method of comparing migraine treatments is a patient preference study, in which the patients are asked to use both treatments and then assign preference to one of the treatments. We would like to test the concept of patient preference as the primary endpoint in a randomised double blind cross-over study, comparing an analgesic with a triptan for the acute treatment of three migraine attacks in patients from the general population, who have not used a triptan or ergot before.

Hypothesis:

Patients prefer naratriptan over paracetamol 1000 mg for the acute treatment of migraine attacks.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the local medical ethics committee

Study design

A randomised, double blind, double-dummy, cross-over study.

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Migraine

Interventions

1. Naratriptan 2.5 mg
2. Paracetamol 1000 mg

Subjects will be randomised to either naratriptan or paracetamol with a cross-over after three attacks. Subjects rate their satisfaction with treatment after each attack. Preference is evaluated after the second treatment period.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Naratriptan, paracetamol

Primary outcome measure

Direction and strength of patient preference on a 10 cm scale ranging from -5 (strong preference for treatment A) to +5 (strong preference for treatment B), where 0 indicates no preference.

Secondary outcome measures

1. Changes in quality of life
2. Pain free rate at 2 hours postdose

Overall study start date

01/01/2005

Completion date

31/12/2005

Eligibility**Key inclusion criteria**

1. The subject is greater than or equal to 18 years of age at visit 1
2. The subject has a current history of migraine with or without aura according to the International Headache Society (IHS) criteria
3. The subject has experienced an average of at least one migraine day per month for six months prior to entry to the study
4. The subject is naïve to the use of 5HT₁ agonists and ergotamine
5. The subject is willing and able to understand and complete questionnaires
6. The subject is willing and able to give informed consent prior to entry into the study

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

40

Key exclusion criteria

1. Subjects with a history suggestive of ischaemic heart disease (IHD) (e.g. angina pectoris) or any atherosclerotic disease which places them at increased risk of coronary ischaemia
2. Subjects with a history of cerebrovascular accident (CVA) or transient ischaemic attack (TIA)
3. Subjects who currently abuse alcohol, analgesics or psychotropic drugs
4. Subjects who have any severe concurrent medical condition which may affect the interpretation in a clinical trial
5. Subjects with a history of basilar, hemiplegic or ophtalmoplegic migraine
6. Subjects with impaired hepatic or renal function
7. Subjects who have a known or suspected hypersensitivity to, intolerance of, or contra-indications to any component of the study medication
8. Females who are pregnant or breastfeeding, and females of childbearing potential who are not using a medically acceptable form of contraception
9. Subjects who have participated in a clinical trial within the previous month or are currently participating in any other clinical research study or clinical trial
10. Subjects with a history of hypertension or a current blood pressure above 160/95 mmHg (measured three times)

Date of first enrolment

01/01/2005

Date of final enrolment

31/12/2005

Locations

Countries of recruitment

Netherlands

Study participating centre

Leiden University Medical Center (LUMC)

Leiden

Netherlands

2300 RC

Sponsor information

Organisation

Leiden University Medical Centre (LUMC) (The Netherlands)

Sponsor details

Department of Neurology
Albinusdreef 2
P.O. Box 9600
Leiden
Netherlands
2300 RC

Sponsor type

Hospital/treatment centre

Website

http://www.lumc.nl/english/start_english.html

ROR

<https://ror.org/027bh9e22>

Funder(s)

Funder type

Industry

Funder Name

GlaxoSmithKline (The Netherlands)

Alternative Name(s)

GlaxoSmithKline plc., GSK plc., GSK

Funding Body Type

Government organisation

Funding Body Subtype

For-profit companies (industry)

Location

United Kingdom

Funder Name

Leiden University Medical Centre (LUMC) (The Netherlands)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration